Opus Genetics Inc (IRD)

Currency in USD
1.070
-0.040(-3.60%)
Closed·
After Hours
1.0700.000(0.00%)
·
IRD Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Earnings results expected in 4 days
Fair Value
Day's Range
1.0691.129
52 wk Range
0.6501.860
Key Statistics
Prev. Close
1.07
Open
1.12
Day's Range
1.069-1.129
52 wk Range
0.65-1.86
Volume
139.97K
Average Volume (3m)
1.06M
1-Year Change
-39.2%
Book Value / Share
0.11
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
IRD Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
6.000
Upside
+460.75%
Members' Sentiments
Bearish
Bullish
ProTips
Stock has taken a big hit over the last week

Opus Genetics Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Opus Genetics Inc Company Profile

Opus Genetics, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of inherited retinal diseases (IRDs). It develops OPGx-LCA5, an early-onset retinal degeneration that is in Phase 1/2 clinical trial for the treatment of LCA5-associated IRD; and OPGx-BEST1 to treat BEST1-associated retinal disease. The company also develops various pre-clinical IRD programs, including OPGx-RHO, a gene therapy that targets autosomal dominant retinitis pigmentosa caused by RHO mutations; OPGx-RDH12 that is designed to restore protein expression and halt functional deterioration in patients with retinal dystrophy caused by mutations in the retinal dehydrogenase gene; OPGx-MERTK, an AAV vector for the treatment of MERTK IRD; OPGx-NMNAT1, a gene augmentation therapy designed to halt functional deterioration in pediatric patients with retinal degenerative disease caused by mutations in the nicotinamide mononucleotide adenylyltransferase 1 gene; and OPGx-CNGB1, an AAV gene therapy for retinitis pigmentosa due to mutations in the CNGB1 gene. In addition, it develops Phentolamine Ophthalmic Solution for reversal of mydriasis, as well as for the treatment of presbyopia and dim light or night vision disturbances; and APX3330, a small-molecule inhibitor of Ref-1 for the treatment of diabetic retinopathy. The company was formerly known as Ocuphire Pharma, Inc. Opus Genetics, Inc. was founded in 2018 and is headquartered in Durham, North Carolina.

Employees
18

Compare IRD to Peers and Sector

Metrics to compare
IRD
Peers
Sector
Relationship
P/E Ratio
−1.1x−4.3x−0.5x
PEG Ratio
0.00−0.190.00
Price/Book
12.6x1.8x2.6x
Price / LTM Sales
4.7x10.1x3.3x
Upside (Analyst Target)
-60.4%45.1%
Fair Value Upside
Unlock25.4%7.4%Unlock

Analyst Ratings

4 Buy
0 Hold
0 Sell
Ratings:
4 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 6.000
(+460.75% Upside)

Earnings

Latest Release
May 15, 2025
EPS / Forecast
-0.24 / -0.29
Revenue / Forecast
4.37M / 2.00M
EPS Revisions
Last 90 days

IRD Income Statement

People Also Watch

0.600
WINT
-11.11%
6.4700
BGLC
-6.64%
1.250
SQNS
-0.79%
63.69
MP
+3.56%
168.10
CRCL
-8.40%

FAQ

What Stock Exchange Does Opus Genetics Trade On?

Opus Genetics is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Opus Genetics?

The stock symbol for Opus Genetics is "IRD."

What Is the Opus Genetics Market Cap?

As of today, Opus Genetics market cap is 63.84M.

What Is Opus Genetics's Earnings Per Share (TTM)?

The Opus Genetics EPS (TTM) is -2.02.

When Is the Next Opus Genetics Earnings Date?

Opus Genetics will release its next earnings report on 07 Aug 2025.

From a Technical Analysis Perspective, Is IRD a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Opus Genetics Stock Split?

Opus Genetics has split 3 times.

How Many Employees Does Opus Genetics Have?

Opus Genetics has 18 employees.

What is the current trading status of Opus Genetics (IRD)?

As of 04 Aug 2025, Opus Genetics (IRD) is trading at a price of 1.07, with a previous close of 1.07. The stock has fluctuated within a day range of 1.07 to 1.13, while its 52-week range spans from 0.65 to 1.86.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.